Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 7/20 | 0.58 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206692 | 1.00 | ITGAL (0.58) | ITGALITGB2ICAM1ELANEMCHR1 | |
| SCHEMBL5201254 | 0.85 | ITGAL (0.61) | ITGALITGB2ICAM1AR | |
| SCHEMBL5206070 | 0.85 | ITGAL (0.80) | ITGALITGB2ICAM1 | |
| SCHEMBL5206081 | 0.85 | ITGAL (0.80) | ITGALITGB2ICAM1 | |
| SCHEMBL7704334 | 0.80 | ITGAL (0.79) | ITGALITGB2ICAM1 | |
| SCHEMBL13817030 | 0.80 | ITGAL (0.58) | ITGALITGB2ICAM1ELANETMEM97 | |
| SCHEMBL5200782 | 0.79 | ITGAL (0.58) | ITGALITGB2ICAM1ELANEMCHR1 | |
| SCHEMBL5200790 | 0.79 | ITGAL (0.58) | ITGALITGB2ICAM1ELANEMCHR1 | |
| SCHEMBL6314317 | 0.73 | ITGAL (1.00) | ITGALITGB2ICAM1 | |
| SCHEMBL6314324 | 0.73 | ITGAL (1.00) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284973-B1 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2007-06-27 | — | — | EP | claimed |
| US-6699888-B2 | ANTIINFLAMMATORY | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-02 | — | — | US | claimed |
| US-20030225138-A1 | Inhibitors of alpha l beta 2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | US | claimed |
| EP-1284973-A2 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-26 | — | — | EP | claimed |
| WO-2001092253-A2 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2001-12-06 | — | — | WO | claimed |
| EP-1284973-B1 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1284973-B1 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-6699888-B2 | ANTIINFLAMMATORY | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030225138-A1 | Inhibitors of alpha l beta 2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1284973-A2 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-26 | — | — | EP | disclosed |
| WO-2001092253-A2 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225138-A1 | Inhibitors of alpha l beta 2 mediated cell adhesion | ICAM1, VCAM1, SELL | ITGAL 13/4885ITGB2 5/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.